Theriva Biologics Revenue
Biotechnology Research • 
Rockville, Maryland, United States • 21-50 Employees
Theriva Biologics revenue & valuation
| Annual revenue | $1,882,210 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $6,100,000 |
| Total funding | $12,500,000 |
Key Contacts at Theriva Biologics
Steve Hubert
Sr. Director Of Manufacturing
Steven Shallcross
Chief Executive Officer, Chief Financial Officer And Director
Suzanne Sealing
Director Of Accounting
Company overview
| Headquarters | 9605 Medical Center Drive, Suite 270, Rockville, Maryland 20850, US |
| Phone number | +17343327800 |
| Website | |
| NAICS | 541714 |
| Keywords | Oncology, Clinical Development, Drug Discovery, Cancer, Microbiome, Preservation Of Natural Gut Microbiome, Prevention Of C. Dificile Infection, Oncolytic Virus |
| Employees | 21-50 |
| Socials |
Theriva Biologics Email Formats
Theriva Biologics uses 4 email formats. The most common is {first initial}{last name} (e.g., jdoe@syntheticbiologics.com), used 33.3% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@syntheticbiologics.com | 66.6% |
{last name}{last name} | doedoe@syntheticbiologics.com | 25% |
{first initial}{second initial} | jo@therivabio.com | 8.3% |
About Theriva Biologics
Theriva Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need. The Company advanced into oncology through the acquisition of VCN Biosciences, S.L. (VCN), who have developed a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient’s immune system. The Company’s lead candidates are: (1) VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment; (2) SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) Clostridioides difficile infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR), and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (3) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Theriva Biologics has 8 employees across 6 departments.
Departments
Number of employees
Funding Data
Explore Theriva Biologics's funding history, including investment rounds, total capital raised, and key backers.
Theriva Biologics Tech Stack
Discover the technologies and tools that power Theriva Biologics's digital infrastructure, from frameworks to analytics platforms.
CDN
Security
WordPress themes
JavaScript libraries
Page builders
JavaScript libraries
JavaScript libraries
Programming languages
Security
Blogs
Analytics
Spain
Netherlands
South AfricaFrequently asked questions
4.8
40,000 users
